Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | FURIN | P09958 | 4/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24703694 | 0.90 | SMN1; SMN2 (0.32) | SMN1; SMN2SIRT6SIRT1FURINREN | |
| SCHEMBL18818915 | 0.86 | REN (0.34) | SMN1; SMN2SIRT6SIRT1FURINREN | |
| SCHEMBL23106115 | 0.86 | SMN1; SMN2 (0.33) | SMN1; SMN2SIRT6SIRT1FURINREN | |
| SCHEMBL25070715 | 0.83 | FURIN (0.31) | SMN1; SMN2SIRT6SIRT1FURINREN | |
| SCHEMBL22692385 | 0.83 | SIRT6 (0.38) | SMN1; SMN2SIRT6SIRT1FURINNOD1 | |
| SCHEMBL21915906 | 0.81 | SIRT6 (0.36) | SMN1; SMN2SIRT6SIRT1FURINNOD1 | |
| SCHEMBL25070732 | 0.80 | SIRT6 (0.41) | SMN1; SMN2SIRT6SIRT1FURINNOD1 | |
| SCHEMBL21914949 | 0.79 | C3AR1 (0.34) | SMN1; SMN2SIRT6SIRT1FURINC3AR1 | |
| SCHEMBL24173258 | 0.79 | C3AR1 (0.34) | SMN1; SMN2SIRT6SIRT1FURINC3AR1 | |
| SCHEMBL22198634 | 0.79 | C3AR1 (0.34) | SMN1; SMN2SIRT6SIRT1FURINC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2021-07-01 | — | — | US | disclosed |
| US-10624968-B2 | Compounds for treating cancer | Bicyclerd Limited (GB) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624968-B2 | Compounds for treating cancer | TP53, VHL, MYC | SMN1; SMN2 3956/4885SIRT6 1621/4885SIRT1 1018/4885 |
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | SMN1; SMN2 2005/4885SIRT6 2884/4885SIRT1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.